Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial

Grinsztejn, Beatriz; De Castro, Nathalie; Arnold, Vincent; Veloso, Valdiléa G.; Morgado, Mariza; Pilotto, José Henrique; Brites, Carlos; Madruga, José Valdez; Barcellos, Nêmora Tregnago; Santos, Breno Riegel; Vorsatz, Carla; Fagard, Catherine; Santini-Oliveira, Marilia; Patey, Olivier; Delaugerre, Constance; Chêne, Geneviève; Molina, Jean-Michel

Published in

Elsevier, The Lancet Infectious Diseases, 6(14), p. 459-467, 2014

DOI: 10.1016/s1473-3099(14)70711-x

Tools

Export citation

Search in Google Scholar

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial

Journal article published in 2014 by Beatriz Grinsztejn, Nathalie De Castro, Vincent Arnold, Valdiléa G. Veloso, Mariza Morgado, José Henrique Pilotto

, Carlos Brites, José Valdez Madruga, Nêmora Tregnago Barcellos, Breno Riegel Santos, Carla Vorsatz, Catherine Fagard, Marilia Santini-Oliveira, Olivier Patey, Constance Delaugerre and other authors.

This paper is available in a repository.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): A multicentre, phase 2, non-comparative, open-label, randomised trial